WATERS CORP

How rising U.S. Treasury yields are squeezing S&P 500 Health‑Care stocks—especially Waters Corp.—and what investors can do to spot hidden risks and growth opportunities.

Waters Corp’s Q4 2026 10‑Q shows a modest revenue decline, but service income grows 16.7 %, while the BDS acquisition boosts product sales and adds strategic synergies—yet the company reports an operating loss and tighter cash flow, highlighting the…

Waters Corp’s Q1 2026 report shows a 91% revenue jump driven by BDS acquisition, but rising losses, debt and looming patent cliffs highlight the need for strategic integration, pricing, and R&D investment to secure future growth in diagnostics and a…

Waters Corporation’s 2026 senior notes offering via Augusta SpinCo boosts long‑term growth funding, offering tiered maturities, rising rates, and strong credit guarantees.

Waters Corp’s latest filings reveal a smart senior‑notes debt program, S‑3ASR flexibility, and a SpinCo acquisition to boost high‑throughput LC tools for pharma R&D.

Waters Corporation powers pharma and environmental research with high‑performance liquid chromatography and mass‑spectrometry, driving 5.8% revenue growth, strong margins, and resilient free cash flow.

Waters Corp’s Q4 results show modest revenue growth, EPS beating expectations, and a shift to subscription sales—highlighting its BD merger’s impact and future growth strategy.

Waters Corp’s Q4 2025 earnings hit $1.05B, spurred by high‑throughput chemistry tools and a new Empower subscription model, while its $18B BD Biosciences deal positions it for future diagnostics growth—despite short‑term revenue dips.

Institutional investors back Waters Corp as it expands digital chemistry and service‑based revenue, positioning itself for growth in the $1.3 bn global HPLC market.

Waters Corp. gains “Outperform” upgrades and bullish RSI as its LC‑MS innovations, FDA clearance, and strategic biopharma partnership boost investor confidence.